LncRNA FENDRR Inhibits Mitochondrial Apoptosis via TET2 ‐Mediated DNA Demethylation of MFN1 in NSCPO
Oral Diseases · 2025
DOI: 10.1111/odi.70035 ↗At a glance
Journal article in Oral Diseases, 2025. Written by Caihong Wu and 7 co-authors. Institution: Stomatological Hospital, Affiliated Suzhou Vocational Health College, Suzhou, China. Major MEDLINE topics: RNA, Long Noncoding, Apoptosis, Proto-Oncogene Proteins, Cleft Palate. 56 references. Funded by: National Natural Science Foundation of China, Jiangsu Province Capability Improvement Project through Science, Technology, and Education-Jiangsu Provincial Research Hospital Cultivation Unit, Jiangsu Provincial Medical Innovation Center.
Abstract (original language)
Background
Non‐syndromic cleft palate only (NSCPO) and non‐syndromic cleft lip with or without cleft palate (NSCL/P) are distinct malformations with different or partially overlapping etiologies. While NSCL/P has been extensively studied, NSCPO remains relatively understudied. Emerging evidence suggests that long noncoding RNAs (lncRNAs) contribute to craniofacial development, potentially by regulating apoptosis.
Methods
This study investigated the role of FENDRR , a lncRNA previously found to be downregulated in NSCL/P, in NSCPO pathogenesis. FENDRR expression in NSCPO tissues was analyzed via RT‐qPCR and fluorescence in situ hybridization. Apoptosis in human embryonic palatal mesenchymal (HEPM) cells was assessed using Western blotting, flow cytometry, and TUNEL assays. Bioinformatics, methylation‐specific PCR, dual‐luciferase reporter assays, and RNA immunoprecipitation were employed to examine FENDRR 's interaction with MFN1 .
Results
FENDRR was significantly reduced in NSCPO tissues. FENDRR knockdown disrupted mitochondrial dynamics and activated mitochondrial apoptosis in HEPM cells. Mechanistically, FENDRR formed an RNA–DNA triplex with the MFN1 promoter, recruiting TET2 to promote MFN1 transcription via promoter demethylation.
Conclusions
FENDRR enhances MFN1 expression, maintains mitochondrial fusion, and suppresses apoptosis in HEPM cells. This study provides novel insights into the regulatory role of lncRNAs in NSCPO pathogenesis and identifies FENDRR as a potential therapeutic target.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Stomatological Hospital, Affiliated Suzhou Vocational Health College, Suzhou, China.
- Department of Orthodontics, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China.
- State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Nanjing Medical University, Nanjing, China.
- Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing, Jiangsu, China.
- Department of Stomatology, The First People's Hospital of Lianyungang City, Affiliated to Nanjing Medical University, Lianyungang, China.
- Savaid Stomatology School, Hangzhou Medical College, Hangzhou, China.
ORCID profiles: Junqing Ma
Funding
- National Natural Science Foundation of China
- Jiangsu Province Capability Improvement Project through Science, Technology, and Education-Jiangsu Provincial Research Hospital Cultivation Unit
- Jiangsu Provincial Medical Innovation Center
- "Seeking Truth Talent Project", Hangzhou Medical College;
Cite
APA
Wu, C., Liu, H., Shan, Z., Xia, Y., Zhao, P., Zhang, Z., Yueguang, G., & Ma, J. (2025). LncRNA FENDRR Inhibits Mitochondrial Apoptosis via TET2 ‐Mediated DNA Demethylation of MFN1 in NSCPO. Oral Diseases. https://doi.org/10.1111/odi.70035
Vancouver
Wu C, Liu H, Shan Z, Xia Y, Zhao P, Zhang Z, et al. LncRNA FENDRR Inhibits Mitochondrial Apoptosis via TET2 ‐Mediated DNA Demethylation of MFN1 in NSCPO. Oral Diseases. 2025. doi:10.1111/odi.70035
BibTeX
@article{Wu2025,
author = {Wu, Caihong and Liu, Haojie and Shan, Zerui and Xia, Yu and Zhao, Panpan and Zhang, Zhongyin and Yueguang, Gu and Ma, Junqing},
title = {LncRNA FENDRR Inhibits Mitochondrial Apoptosis via TET2 ‐Mediated DNA Demethylation of MFN1 in NSCPO},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.70035}
}
EUVIMED